Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
about
Cost-utility analysis comparing laparoscopic vs open aortobifemoral bypass surgeryRoutine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness AnalysisHow to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America.Professional oral healthcare for preventing nursing home-acquired pneumonia: a cost-effectiveness and value of information analysis.Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.We need a NICE for global development spendingThe cost-effectiveness of an eradication programme in the end game: Evidence from guinea worm disease.Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness".Adapting Pharmacoeconomics to Shape Efficient Health Systems en Route to UHC - Lessons from Two Continents.Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case.Cost-effectiveness of adding indoor residual spraying to case management in Afghan refugee settlements in Northwest Pakistan during a prolonged malaria epidemic.Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage.Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.Community-Based Interventions for Newborns in Ethiopia (COMBINE): Cost-effectiveness analysis.Recombinant Parathyroid Hormone Versus Usual Care: Do the Outcomes Justify the Cost?Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa.Calculation of the disease burden associated with environmental chemical exposures: application of toxicological information in health economic estimation.Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries.Progressive realisation of universal health coverage: what are the required processes and evidence?Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: a systematic review.Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs.Reflecting the real value of health care resources in modelling and cost-effectiveness studies-The example of viral load informed differentiated care.Distributional cost-effectiveness analysis in low-and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia.Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.Cost-effectiveness analysis of diarrhoea management approaches in Nigeria: A decision analytical model.Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial.Combination of indoor residual spraying with long-lasting insecticide-treated nets for malaria control in Zambezia, Mozambique: a cluster randomised trial and cost-effectiveness study protocol.Cost-effectiveness of interventions to control cardiovascular diseases and diabetes mellitus in South Asia: a systematic review.The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.Supporting the development of a health benefits package in Malawi.The cost of preventing undernutrition: cost, cost-efficiency and cost-effectiveness of three cash-based interventions on nutrition outcomes in Dadu, Pakistan.The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.Protecting Adolescents in Low- And Middle-Income Countries from Interpersonal Violence (PRO YOUTH TRIAL): Study Protocol for a Cluster Randomized Controlled Trial of the Strengthening Families Programme 10-14 ("Familias Fuertes") in Panama.Is contraceptive self-injection cost-effective compared to contraceptive injections from facility-based health workers? Evidence from UgandaRevisiting Health Rights Litigation and Access to Medications in Costa Rica: Preliminary Evidence from the Cochrane Collaboration ReformThe impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness studyPotential effect of household contact management on childhood tuberculosis: a mathematical modelling study
P2860
Q33828725-EDA7E154-F819-47CC-A18E-F402FE7ACAD6Q35957814-0C7E4C70-5C70-415C-AF57-3184C000A506Q37540362-5D85418D-CB6E-408A-A356-708D47A7C18BQ38658318-C0EA4E76-1EEE-4802-9455-C207B150A870Q38737493-40BE8F6D-F434-410E-8F54-70F9B42C123BQ40041518-C5542521-ACCA-498F-B2E2-70B647FBA248Q41425958-903CD712-6238-45F2-9305-B5487C3E7F15Q41923683-E64FFD93-2DC8-4E05-862C-350CFDD5FE19Q42257080-908F5819-8187-47D5-B675-188DD9F51A08Q42700388-55D99DA6-BF0F-4D86-A3E8-79805FD0AE8AQ44032580-CB7F08B3-9830-4D78-B37F-CA3D1D9A2D66Q44039049-3F9CFD17-862B-4DD9-8B58-7B1231F4C328Q45323637-55427854-D991-4CD8-86AA-C4FD6F7FF6F5Q46191148-16C6DC18-B090-4916-8C13-057390BAED58Q46302310-037A096C-3561-4A3D-836A-53E98ACF6F50Q46438384-2143A2B1-9BDA-48C8-9264-9352A4D8C1CFQ46543437-B6940B64-9D60-47B3-8F7E-9A72321ACBC9Q47096835-568232A2-790A-4A94-A2F4-2741B4374258Q47103647-B9FEC399-DA24-4E1C-804B-D64514EE9898Q47138800-20BCA57A-DD88-4ACD-BD2C-9B84D328971CQ47255991-66DF5F58-005C-4499-B393-CE329F090056Q47420352-5860BF48-3D14-4830-8A5D-D7E7614110B0Q47547664-0F34D01E-0C81-42FB-9CD7-439789F61022Q47553077-3C328BF2-CDA7-44E2-8802-49E4D0BFCF07Q47558989-2869850C-ABB2-4338-B866-73410085D790Q47564040-E977B93D-7B52-4654-88EA-89946D91A951Q48111916-DEE6BF6F-4AAE-4A71-89F1-AEC13A91D0EFQ48376409-EDEF1790-CB22-42D1-8A12-2B937DD7F88EQ49373622-BD19AA84-63C1-45A9-82EA-D8238C65938AQ51736828-38970C52-DB36-43A8-B8D5-41A81A85FCE1Q52609148-803FF22D-90F1-4EAC-91FA-27C18008260DQ52656286-F5FAA076-8890-4E74-861D-528DCCDC90F0Q54986219-D2DB3724-1312-49E0-90C8-C919C96964E5Q55284569-51A61D27-DB7F-43E8-8C89-92754343C09FQ55313663-F26AB931-A833-4D2E-9C14-98348412FED2Q55434834-DB79137D-B17D-4335-BAF2-78827F0E323FQ56910623-C61120FF-F300-484C-9A40-7D6E108157FAQ57094087-AEDA25DC-3799-4D0C-A2B0-82894DFCD099Q57395637-B2FDBB70-456E-48AA-8CB2-49E39E564943Q57557443-8F4CD496-8D06-4FF7-862C-CB57BD349604
P2860
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Country-Level Cost-Effectivene ...... the Need for Further Research.
@en
Country-Level Cost-Effectivene ...... the Need for Further Research.
@nl
type
label
Country-Level Cost-Effectivene ...... the Need for Further Research.
@en
Country-Level Cost-Effectivene ...... the Need for Further Research.
@nl
prefLabel
Country-Level Cost-Effectivene ...... the Need for Further Research.
@en
Country-Level Cost-Effectivene ...... the Need for Further Research.
@nl
P2093
P2860
P1433
P1476
Country-Level Cost-Effectivene ...... the Need for Further Research.
@en
P2093
Beth Woods
Karl Claxton
Mark Sculpher
Paul Revill
P2860
P304
P356
10.1016/J.JVAL.2016.02.017
P577
2016-12-01T00:00:00Z